{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:24:01Z","timestamp":1773415441144,"version":"3.50.1"},"reference-count":65,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,7,28]],"date-time":"2008-07-28T00:00:00Z","timestamp":1217203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Pegylated interferon with ribavirin (Peg\/R) is the most effective therapy for chronic hepatitis C virus (HCV) but its utility and effectiveness after liver transplantation has been difficult to assess. We evaluated efficacy, tolerability, and safety of Peg\/R in liver transplant candidates and recipients with HCV cirrhosis. We searched medical databases and conference proceedings between January 1999 and January 2008 selecting randomized and nonrandomized studies. Primary end points meta\u2010analytically were: (1) sustained viral response (SVR) and (2) histological response. Secondary end points were: (1) treatment discontinuation, (2) mortality, and (3) rejection episodes. Pegylated interferons using either 1\u20131.5\u2003mcg\/kg of pegylated interferon alpha\u20102b or 180\u2003\u03bcg (pegylated interferon alpha\u20102a combined with ribavirin 800\u20131200\u2003mg\/day were the most effective compared to any other regimen or no therapy. In three pretransplant studies the median SVR was 19.6% (19.6\u201350%). In six postransplant studies where a meta\u2010analysis was done the cumulative risk difference in SVR was 0.31% (95% CI, 0.18\u20130.44, <jats:italic>p<\/jats:italic>\u2003&lt;\u20030.001). However histological response was not significantly better compared to no therapy or other antiviral regimens. There were no significant differences in discontinuation of therapy, acute or chronic rejection or mortality between optimal Peg\/R <jats:italic>vs<\/jats:italic> no treatment or other regimens. Hence pegylated interferon plus ribavirin in full doses is effective pre and post transplant but has a low SVR rate. To date no significant histological improvement has been reported.<\/jats:p>","DOI":"10.1111\/j.1365-2893.2008.01019.x","type":"journal-article","created":{"date-parts":[[2008,7,29]],"date-time":"2008-07-29T01:57:31Z","timestamp":1217296651000},"page":"699-709","source":"Crossref","is-referenced-by-count":91,"title":["Pegylated\u2010interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta\u2010analysis of prospective controlled studies"],"prefix":"10.1111","volume":"15","author":[{"given":"E.","family":"Xirouchakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Triantos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Manousou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sigalas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Calvaruso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Corbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Leandro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Patch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,9,19]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32418"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.001"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000149696.76204.38"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20865"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01362.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03364.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50095"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2001.27869"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.02.015"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806303182605"},{"key":"e_1_2_7_16_2","volume-title":"Meta\u2010Analysis in Medical Research","author":"Leandro G","year":"2004"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.02.041"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2006.00753.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.08.020"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.04.020"},{"issue":"1","key":"e_1_2_7_21_2","article-title":"Treatment of cirrhotic patients with HCV referred for liver transplantation using an escalating dose regimen of pegylated interferon alpha\u20102A and ribavirin (Abstract)","volume":"44","author":"Massoumi H","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_7_22_2","article-title":"Hepatic function is a strong predictive factor of efficacy and safety of antiviral therapy in portal hypertensive hepatitis C virous\u2010related liver cirrhosis (Abstract)","volume":"46","author":"Annicchiarico BE","year":"2007","journal-title":"J Hepatol"},{"issue":"1","key":"e_1_2_7_23_2","article-title":"Maitenance pegylated IFN given once every three weeks prevents relapse of hepatitis C virus (HCV) in decompensated cirrhosis (Abstract)","volume":"44","author":"Thorat VK","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_7_24_2","first-page":"332A","article-title":"Efficacy and safety of peginterferon alpha\u20102a(40Kd) plus ribavirin in HCV patients with complete cirrhosis (knodell score F4) (Abstract)","volume":"44","author":"Bruno S","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_7_25_2","article-title":"Impact of baseline hepatitis C virus (HCV) RNA and genotype on the efficacy of peginterferon alpha\u20102a (40Kd) plus ribavirin in patients with compensated cirrhosis\/bridging fibrosis (Abstract)","volume":"42","author":"Marcellin P","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"e_1_2_7_26_2","article-title":"Safety and efficacy of antiviral therapy in patients with decompensated cirrhosis associated with chronic Hepatitis C infection (Abstract)","volume":"130","author":"Lim JK","year":"2006","journal-title":"Gastroenterology"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00648.x"},{"issue":"1","key":"e_1_2_7_28_2","article-title":"Preemptive treatment of HCV after liver transplantation is unjustified except for genotype 3A (Abstract)","volume":"46","author":"Merhav HJ","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.09.018"},{"issue":"1","key":"e_1_2_7_30_2","article-title":"Long\u2010term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus (HCV) infection (Abstract)","volume":"44","author":"Kuo A","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20883"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01470.x"},{"issue":"6","key":"e_1_2_7_33_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1155\/2005\/745197","article-title":"Pegylated\u2010interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy","volume":"19","author":"Babatin M","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2003.12.015"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1399-0012.2003.00145.x"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000100481.14514.BB"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20189"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01619.x"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000225827.18034.be"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01261.x"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2005.03795.x"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000129811.93072.1C"},{"issue":"70","key":"e_1_2_7_43_2","first-page":"561","article-title":"Impact of pegylated interferon alfa\u20102a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open\u2010label series","volume":"53","author":"Mukherjee S","year":"2006","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.12.017"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.10.017"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.03.124"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.041"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03363.x"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21121"},{"issue":"11","key":"e_1_2_7_50_2","article-title":"High sustained virological response (SVR) in HCV treatment with peginterferon\u2010alfa 2b and ribavirin after liver transplantation (Abstract)","volume":"5","author":"Gordon F","year":"2005","journal-title":"Am J Transplant"},{"issue":"2","key":"e_1_2_7_51_2","article-title":"Efficacy and safety of prolonged interferon and ribavirin for recurrent hepatitis C following orthotopic liver transplantation (Abstract)","volume":"6","author":"Verna E","year":"2006","journal-title":"Am J Transplant"},{"issue":"2","key":"e_1_2_7_52_2","first-page":"540","article-title":"Comparison of pegylated interferon alpha 2a and ribavirin vs pegylated interferon alpha 2b and ribavirin for treatment of recurrent hepatitis C after liver transplantation (Abstract)","volume":"6","author":"Chadalavada R","year":"2006","journal-title":"Am J Transplant"},{"issue":"1","key":"e_1_2_7_53_2","article-title":"Sustained viral response using PEG INF alfa\u20102b plus ribavirin in patients with recurrent hepatitis C after liver transplantation (Abstract)","volume":"44","author":"Ghalib R","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_7_54_2","article-title":"Adherence to the 80\/80\/80 rule in treatment of HCV recurrence after OLT is strongly associated with sustained virologic response (Abstract)","volume":"44","author":"Chacko K","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"e_1_2_7_55_2","article-title":"Treatment with combination Peginterferon alfa\u20102b and ribavirin of recurrent hepatitis C in liver transplant recipients non responsive to interferon alfa\u20102b and ribavirin (Abstract)","volume":"130","author":"Samanta A","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_2_7_56_2","first-page":"479A","article-title":"Sustained virological response to antiviral therapy for recurrent HCV post liver transplant favorably influences histological progression (Abstract)","volume":"44","author":"Selzner N","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_7_57_2","article-title":"Predictive factors of early and sustained viral response in patients with recurrent hepatitis C after liver transplantation treated with combined therapy (Abstract)","volume":"42","author":"Casanovas\u2010Taltavull T","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_7_58_2","article-title":"Antiviral therapy for HCV\u20101b liver transplant recipients: better results with younger grafts (Abstract)","volume":"42","author":"Benlloch S","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_7_59_2","article-title":"On treatment virological response of 70% in 100 patients treated with combination antiviral therapy for recurrent HCV following liver transplantation (Abstract)","volume":"42","author":"Lilly L","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_7_60_2","article-title":"Treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon and ribavirin (Abstract)","volume":"34","author":"Samuel D","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_7_61_2","article-title":"Pegylated interferon plus ribavirin for the treatment of recurrent HCV infection after liver transplantation (Abstract)","volume":"40","author":"Lorenzini S","year":"2004","journal-title":"J Hepatol"},{"issue":"1","key":"e_1_2_7_62_2","article-title":"Prediction of treatment response to 72 weeks of pegylated interferon alfa\u20102a plus ribavirin for chronic hepatitis C after liver transplantation (Abstract)","volume":"46","author":"Bergk A","year":"2007","journal-title":"J Hepatol"},{"issue":"2","key":"e_1_2_7_63_2","article-title":"Pegylated interferon a\u20102b plus ribavirin in the treatment of post\u2010liver transplant recurrent hepatitis C (Abstract)","volume":"42","author":"Martini S","year":"2005","journal-title":"J Hepatol"},{"issue":"1","key":"e_1_2_7_64_2","article-title":"Multicenter Randomized Trial in HCV\u2010infected patients treated with Peginterferon alfa\u20102a and Ribavirin followed by Ribavirin alone after liver transplantation: final report (Abstract)","volume":"46","author":"Calmus Y","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000196716.07188.c4"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.092064"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2893.2008.01019.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2893.2008.01019.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T02:26:57Z","timestamp":1696991217000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2893.2008.01019.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,19]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1111\/j.1365-2893.2008.01019.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2893.2008.01019.x","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,19]]}}}